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Respiratory syncytial virus (RSV) cpts248/404 is a live-attenuated, temperature-sensitive (ts) vaccine candidate derived
from cold-passaged cpRSV by two rounds of chemical mutagenesis and biological selection. Previous sequence analysis
showed that these two steps introduced three single nucleotide substitutions into the cpRSV parent. Two of these occurred
within the coding sequence for the L protein, and each resulted in a single amino acid substitution: Gln-831-Leu (248
mutation) and Asp-1183-Glu (404-L mutation). The third mutation resulted in a nucleotide substitution at position 9 of the
cis-acting gene start signal of the M2 gene (404-M2 mutation). In the present study, the genetic basis of attenuation of
cpts248/404 was defined by the introduction of each of these mutations (singly or in combination) into a full-length cDNA
clone of cpRSV. Recombinant RSV derived from each mutant cDNA was analyzed to determine the contribution of each
mutation to the ts and attenuation phenotypes of the virus. This analysis showed that the 248 mutation specifies a significant
reduction of plaque formation at 38°C and is responsible for an intermediate level of attenuation in mice. In contrast, the
404-L mutation did not contribute to the ts or attenuation phenotype alone or in combination with other mutations and is thus
an incidental change. Unexpectedly, the 404-M2 mutation alone specified complete restriction of plaque formation at 37°C
and a high level of attenuation in mice. This indicates that the level of temperature sensitivity and attenuation of cpts248/404
can be attributed primarily to the 404-M2 mutation. Thus the cpts248/404 virus contains a set of ts and non-ts attenuating
mutations, which likely accounts for its genetic stability. The recombinant version of this virus, rA2cp248/404, was
phenotypically indistinguishable from cpts248/404 and represents a background into which additional mutations can be
introduced as needed to obtain the desired level of attenuation for successful immunization of the very young human infant.
INTRODUCTION
Human respiratory syncytial virus (RSV) is an envel-
oped, negative-sense, single-stranded RNA virus with a
genome that is 15,222 nucleotides in length and encodes
10 subgenomic mRNAs (Collins et al., 1996). These are
translated into 11 known proteins: four nucleocapsid
proteins, namely, nucleocapsid N protein, phosphopro-
tein P, large polymerase subunit L, and transcription
elongation factor M2–1; three transmembrane envelope
glycoproteins, namely, fusion F protein, attachment G
protein, and small hydrophobic SH protein; two nonstruc-
tural proteins, NS1 and NS2; the matrix M protein; and
the putative negative regulatory factor M2–2. Transcrip-
tion of the viral genes is directed by short, conserved
gene start (GS) and gene end (GE) cis-acting signals that
flank each gene. The RSV strain A2 consensus GS signal
is 39-CCCCGUUUAU/C (shown here in genomic, negative
sense) and is conserved among each of the genes with
the exception of L, which differs by three nucleotides.
The first C nucleotide of the GS signal acts as the mRNA
start site. The less conserved GE signal directs tran-
scription termination and polyadenylation (for review, see
Collins et al., 1996).
As a member of the pneumovirus genus of the family
Paramyxoviridae, RSV is the most common cause of
serious viral bronchiolitis and pneumonia in infants and
children worldwide (Collins et al., 1996). Approximately
1% of all infants are hospitalized before 1 year of age as
a consequence of RSV infection, and approximately
90,000 hospital admissions occur annually in the United
States (La Via et al., 1992). RSV infection is also an
important cause of severe respiratory illness in elderly
(Falsey et al., 1995) and immunocompromised popula-
tions (Milner et al., 1985; Hall et al., 1986; Harrington et
al., 1992). There is a clear need for an effective vaccine
to prevent the severe morbidity associated with RSV
infection. Toward this goal, our laboratory has sought to
develop live, attenuated RSV vaccine candidates.
During the 1960s, a cold-passaged (cp), live attenu-
ated vaccine candidate, cpRSV, was derived from a wild-
type (wt) RSV subgroup A isolate (A2) by passage in
human embryonic kidney (HEK) cells, followed by 52
passages in bovine embryonic kidney cells at progres-
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sively lower temperatures (final temperature 26°C)
(Friedewald et al., 1968). Subsequently, cpRSV was
shown to be highly attenuated in adults and seropositive
children but incompletely attenuated in the upper respi-
ratory tract of seronegative children (Friedewald et al.,
1968; Kim et al., 1971; Karron et al., 1997). Although
cpRSV is neither cold adapted nor temperature sensitive
(ts), it exhibits an attenuation (att) phenotype in the re-
spiratory tract of chimpanzees and humans, which is
referred to as a ‘‘host-range’’ restriction because it oper-
ates in vivo but not in cell culture (Friedewald et al., 1968;
Kim et al., 1971; Crowe et al., 1994b; Karron et al., 1997;
Whitehead et al., 1998). Nucleotide sequence analysis of
cpRSV revealed that it possesses five amino acid
changes, located in the N (one change), F (two), and L
(two) proteins (Connors et al., 1995). When transferred
into recombinant RSV, this set of five cp mutations fully
reconstituted the att phenotype of cpRSV in the respira-
tory tract of chimpanzees (Whitehead et al., 1998). To
increase the level of attenuation, additional mutations
were introduced into cpRSV by chemical mutagenesis
with 5-fluorouracil, followed by biological selection for
temperature sensitivity (Crowe et al., 1994a,b). A ts de-
rivative, cpts248, which has a shut-off temperature of
38°C, was isolated following a single round of mutagen-
esis. Nucleotide sequence analysis of cpts248 revealed
a single nucleotide substitution in the L gene, leading to
the amino acid change Gln-831-Leu (Crowe et al., 1996).
Following an additional round of mutagenesis of cpts248,
a more ts derivative, cpts248/404, was isolated and
found to be more attenuated than its predecessor in
mice and chimpanzees (Crowe et al., 1994a). The ge-
nome of cpts248/404 had two additional mutations: a
single nucleotide change in the GS signal of the M2 gene
and a single nucleotide change in the L gene that spec-
ified the amino acid change Asp-1183-Glu (Firestone et
al., 1996).
In the present study, the three mutations of cpts248
and cpts248/404 were introduced singly and in combi-
nation into a cDNA of RSV that is identical at the amino
acid level with cpRSV and thus provides for unambigu-
ous characterization of the effects of the additional mu-
tations. Analysis of the ts and att phenotypes of the
recovered viruses led to the unexpected observation that
the major attenuating mutation in cpts248/404 is a ts
mutation in a cis-acting regulatory region of the genome,
the M2 GS signal.
RESULTS
Production of recombinant RSV
The role of the 248 and 404 mutations in specifying the
ts and att phenotypes of cpts248/404 was evaluated by
their introduction into a recombinant version of cpRSV,
which is the appropriate genetic background because
the cpts248 and cpts248/404 viruses were derivatives of
this parental virus. As described previously (Whitehead
et al., 1998), the original wt recombinant RSV (Collins et
al., 1995) differed at the amino acid level from wtRSV
HEK-7, the progenitor for the biologically derived viruses,
at two positions in the F protein. The two positions were
changed (the two amino acid substitutions are called
‘‘HEK’’ mutations) to make the wt recombinant virus
correspond to wtRSV HEK-7. Thus, there is complete
homology at the amino acid level between the genetic
backgrounds of the biological and recombinant viruses,
permitting direct comparison and unambiguous charac-
terization of introduced mutations. Also, as described
previously, six translationally silent restriction enzyme
sites were introduced into the L gene to facilitate engi-
neering and serve as markers to ensure the integrity of
the L gene, and these had no effect on replication in vitro
or in vivo (Juhasz et al., 1997; Whitehead et al., 1998). In
addition, recombinant cpRSV (designated rA2cp) con-
tains the five cp amino acid substitutions, which recon-
stitute its att phenotype in chimpanzees such that it is
indistinguishable from biologically derived cpRSV (White-
head et al., 1998). In the recombinant virus, the HEK and
cp changes are each marked by the introduction of a
translationally silent restriction site, so that the presence
of the engineered sequence in cDNA and recovered
virus can be readily monitored.
A total of six genetically distinct recombinant viruses
involving the 248, 404-L, and 404-M2 mutations was
generated for analysis. The 248, 404-M2, and 404-L mu-
tations were introduced singly into rA2cp to produce
rA2cp248, rA2cp404-M2, and rA2cp404-L. Recombinant
virus rA2cp248 could be compared directly with its bio-
logically derived counterpart, cpts248. To investigate the
effect of interactions between the mutations, both the
404-M2 and 404-L mutations were introduced separately
into rA2cp248. This generated rA2cp248/404-M2 and
rA2cp248/404-L, which along with rA2cp404-M2 and
rA2cp404-L represent novel viruses having no genetic
counterpart in the biologically derived cpts248/404 virus
lineage. The combination of all three mutations, to create
rA2cp248/404, was expected to be phenotypically equiv-
alent to vaccine candidate virus cpts248/404. Each of the
three mutations was made such that a translationally
silent restriction site was introduced nearby (Table 1),
providing a means of rapidly confirming the presence of
an engineered sequence. Also, the 248 codon change in
recombinant virus was designed to involve two nucleo-
tide substitutions (Table 1), whereas in the biologically
derived virus a single nucleotide substitution was in-
volved. The introduction of a second nucleotide change
in recombinant virus would reduce the possibility of
same-site reversion to the wt assignment, thus increas-
ing genetic stability. Using RT-PCR and restriction frag-
ment analysis, each of the recombinant viruses was
confirmed to contain the appropriate 248, 404-M2, and/or
404-L mutation (data not presented), as well as each of
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the five cp mutations, the six L-gene site mutations, and
the two F-gene HEK-7 mutations present in the rA2cp
virus (Whitehead et al., 1998).
As a general rule, recombinant viruses possessed the
desired introduced mutations. However, on several oc-
casions recombinant viruses were shown to lack sets of
neighboring mutations in the L gene. It was later discov-
ered that the full-length cDNA plasmid used in these
transfections contained a single nucleotide deletion at
position 10991, which is adjacent to the 248 mutation and
contained within the mutagenic oligonucleotide primer.
Transfections using cDNA bearing this deletion repeat-
edly yielded virus that had corrected the deletion pre-
sumably by recombination with the pTM1-L expression
plasmid containing the wt L-gene coding region. This
was confirmed by the observation that genetic markers
surrounding the deletion were not present in the genome
of the resulting virus, with markers up to 2400 nucleo-
tides from the deletion site being lost. This homologous
recombination to repair a defective genome has also
been demonstrated in the Sendai virus rescue system
(Garcin et al., 1995). Transfections using intact cDNA
without the 10991 deletion yielded virus containing all of
the genetic markers as planned.
Temperature sensitivity of recombinant viruses
The level of temperature sensitivity of the recombi-
nant viruses, as determined by their ability to form
plaques at various temperatures, is presented in Table
2, with the viruses grouped according to their level of
temperature sensitivity. The 248 mutation in the L gene
indeed confers the ts phenotype as indicated by the
acquisition of temperature sensitivity by rA2cp248,
which had been made by introducing the 248 mutation
into rA2cp. This was expected because the mutation
was the only sequence difference between cpRSV and
cpts248 (Crowe et al., 1996). The level of temperature
sensitivity of rA2cp248 is equivalent to that of its bio-
logically derived counterpart, cpts248 (38°C shut-off
temperature), confirming that it is the sole contributor
to the ts phenotype of cpts248.
In contrast, the 404-L mutation did not confer the ts
phenotype onto rA2cp nor did it augment the level of
temperature sensitivity of any virus into which it was
introduced. This may be due to the conservative nature
of the substitution (Asp to Glu) and suggests that the
404-L mutation is an incidental mutation lacking detect-
able biological activity, which was confirmed by its lack
of effect in vivo (see below).
The 404-M2 mutation in the M2 GS signal sequence
confers a high level of temperature sensitivity as indi-
cated by the acquisition of temperature sensitivity by
rA2cp404-M2, which had been made by introducing
the 404-M2 mutation into rA2cp. The level of temper-
ature sensitivity of rA2cp404-M2, as well as rA2cp248/
404-M2 and rA2cp248/404, is equivalent to that of the
biologically derived cpts248/404 virus. This indicates
that the effects of the 248 and 404-M2 mutations are
nonadditive. Rather, the temperature sensitivity spec-
ified by the 248 mutation in cpts248/404 and rA2cp248/
404 is masked by that specified by the 404-M2 muta-
tion.
Level of replication of recombinant
viruses in BALB/c mice
The level of replication of wtRSV HEK-7, the biolog-
ically derived mutant viruses, and the recombinant
viruses was compared in the nasal turbinates and
TABLE 1
Introduction of the 248, 404-L, and 404-M2 Mutations into Full-Length cDNA Clones to Create Recombinant RSV
Mutation Gene
Nucleotide
positiona
Restriction
marker
(cleavage site) Sequence changesb
Amino acid
position
Amino acid
change
248 L 10990
SphI
(10986)
wt: ACT CAT GCT C*AA GCAc
mut: ACG CAT GCT CTG GCA
831 Gln . Leu
404-M2 M2-GS 7606
NruI
(7612)
wt: GGGGCAAA*T ATG TCA CGA
mut: GGGGCAAAC ATG TCG CGA
123456789 10
— noncoding
404-L L 12047
XhoI
(12042)
wt: CTT CCA TTG GA*T TGT
mut: CTT CCA CTC GAG TGT
1183 Asp . Glu
a The nucleotide position shown is for the nucleotide change (*) leading to an amino acid substitution in the biologically derived mutant of wt RSV.
Numbering includes the one nucleotide insertion in the NS2-N intergenic region of recombinant virus.
b Nucleotide changes (positive sense) are shown boxed. Restriction enzyme recognition sites that were intentionally cointroduced as genetic
markers are underlined. The sequence is presented in coding triplets and each single nucleotide change in biologically derived virus resulting in a
missense change is indicated (*). Nucleotides of the M2-GS signal are numbered.
c Two nucleotide changes were made to increase genetic stability.
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lungs of BALB/c mice following intranasal inoculation
with 106 pfu of virus (Table 2). Recombinant virus
rA2cp248 exhibited a 4- and 15-fold reduction in rep-
lication in the nasal turbinates and lungs, respectively,
compared with rA2cp, indicating that introduction of
the 248 mutation confers an intermediate level of at-
tenuation. The replication of rA2cp248 and its biolog-
ical counterpart cpts248 was similar in both the nasal
turbinates and lungs.
As expected from its lack of temperature sensitivity,
the rA2cp404-L virus did not show a decrease in rep-
lication in either the nasal turbinates or lungs of mice.
Furthermore, the 404-L mutation did not alter the in
vivo replication of any virus into which it was intro-
duced.
The rA2cp404-M2 virus was more attenuated than
rA2cp248, and it was 60- and 30-fold more restricted in
replication in the upper and lower respiratory tract, re-
spectively, than rA2cp. This marked restriction of repli-
cation was observed for each recombinant virus bearing
the 404-M2 mutation, demonstrating the dominant effect
this mutation has on the att phenotype, as well at the
nonadditive nature of the 248 and 404-M2 mutations.
Replication of either rA2cp404-M2 or rA2cp248/404 was
equivalent to that of the biologically derived cpts248/404
virus, confirming that the recombinant virus is a pheno-
typically equivalent reconstruction of the biologically de-
rived virus.
DISCUSSION
The ability to recover infectious RSV from cDNA has
allowed us to explore the genetic determinants of the ts
and att phenotypes of cpts248/404, currently our leading
live-attenuated RSV vaccine candidate. The most surpris-
ing finding from our studies was that the single nucleo-
tide substitution at position 9 of the M2 GS signal spec-
ified the ts and att phenotypes. This was surprising for
three reasons. First most of the previous mutations that
we have identified in RSV and influenza virus ts mutants
each involve an amino acid substitution in a viral protein,
most frequently in a polymerase subunit (Lawson et al.,
1992; Crowe et al., 1996; Juhasz et al., 1997). Second this
is the first report of a mutation in a cis-acting regulatory
sequence of a negative-sense, single-stranded RNA vi-
rus that confers the ts and att phenotypes. Nevertheless,
several ts mutations have been described in the 59- and
39-noncoding regions of picornaviruses (Racaniello and
Meriam, 1986; Dildine et al., 1991; Jacobson et al., 1993;
Gutierrez et al., 1997; Rinehart et al., 1997). Third it was
remarkable that a viable mutant virus with a nucleotide
substitution at position 9 in a GS signal could be isolated
because saturation mutagenesis of the GS signal using
a transcriptionally active RSV minigenome system indi-
cated that any substitution at position 9 almost com-
pletely eliminated transcription (Kuo et al., 1997). In light
of this finding, we reexamined and confirmed the results
from the minigenome system (data not shown). The ef-
TABLE 2
The 248 and 404-M2 Mutations Are Temperature-Sensitive, Attenuating Mutations, Whereas the 404-L Mutation Is Not
Virusa
Mutations
Mean virus titer (log10pfu/ml) at indicated
temperature (°C)
Shut-off
temperatureb
Mean titer in micec
(log10pfu/g tissue)
248 404-M2 404-L 32 36 37 38 39 40
Nasal
Turbinates Lung
wtRSV HEK-7d 5.9 5.9 5.8 6.0 5.8 5.7 .40 4.4 6 0.02 4.9 6 0.08
rA2cp 5.8 5.5 5.5 5.2 5.1 5.0 .40 4.0 6 0.20 3.8 6 0.21
rA2cp404-L X 5.9 5.9 5.8 5.8 5.5 5.4 ,40 3.6 6 0.07 4.4 6 0.08
cpRSVd 5.8 5.8 5.8 5.7 5.6 5.4 .40 4.3 6 0.04 4.4 6 0.18
rA2cp248 X 6.0 5.6 4.7* 2.5* ,0.7 ,0.7 38 2.8 6 0.10 3.2 6 0.04
rA2cp248/404-L X X 5.9 5.7 4.4* 1.7* ,0.7 ,0.7 38 2.7 6 0.10 3.5 6 0.07
cpts248d X 6.1 5.7 4.4* 3.4* ,0.7 ,0.7 38 3.4 6 0.07 3.1 6 0.05
rA2cp/404-M2 X 6.1 5.5* ,0.7 ,0.7 ,0.7 ,0.7 37 2.2 6 0.10 2.3 6 0.18
rA2cp248/404-M2 X X 5.7 4.5* ,0.7 ,0.7 ,0.7 ,0.7 37 2.2 6 0.14 1.8 6 0.13
rA2cp248/404 X X X 5.7 4.6* ,0.7 ,0.7 ,0.7 ,0.7 37 2.2 6 0.14 1.8 6 0.11
cpts248/404d X X X 5.5 4.2* ,0.7 ,0.7 ,0.7 ,0.7 37 2.4 6 0.22 2.2 6 0.20
a Recombinant viruses (r) all contain the HEK-7 F-gene mutations and the L-gene sites markers (Whitehead et al., 1998).
b Shut-off temperature is defined as the lowest restrictive temperature at which a 100-fold or greater reduction in titer is observed and is indicated
by boxes.
c Mice in groups of five were administered 106 pfu of the indicated virus intranasally under light anaethesia on day 0 and killed on day 4. Virus titer
was determined in the nasal turbinates and lung tissues and is shown as mean titer 6 standard error (log10pfu/g tissue).
d Biologically derived viruses.
* Pin-point plaque size.
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fect of this 404-M2 mutation on the expression of M2
mRNA and protein at permissive and restrictive temper-
atures is currently under investigation in our laboratory.
The GS signal of the M2 gene overlaps the translation
initiation codon of this gene, which places the 404-M2
mutation at the 21 position relative to the AUG initiation
codon (as shown in Table 1). This is predicted not to
adversely affect the ‘‘translational context’’ by analogy to
other systems because the C nucleotide substitution at
this position may result in a slight translational advan-
tage (Kozak, 1987).
Another surprising observation from the present inves-
tigation was the high level of temperature sensitivity and
attenuation specified by the 404-M2 mutation. In general,
respiratory viruses that have sustained single point mu-
tations leading to amino acid substitutions that specify
the ts phenotype are restricted in replication at 38–40°C
(Spring et al., 1975; Shimizu et al., 1982; Lawson et al.,
1992; Crowe et al., 1994b; Subbarao et al., 1995). In con-
trast, recombinant RSV bearing the 404-M2 mutation was
highly restricted in plaque formation at 37°C, as well as
in replication in the respiratory tract of mice. Previous
efforts to derive viruses with a 37°C shut-off temperature,
a level of temperature sensitivity required for attenuation
in humans, have required considerable effort, such as
the accumulation of two or more amino acid substitution
mutations into one virus using viral genetic techniques or
successive cycles of mutagenesis and biological selec-
tion (Murphy et al., 1978, 1982; Crowe et al., 1994a, 1995;
Subbarao et al., 1995).
The biological effects of the second attenuating ts
mutation in cpts248/404, the 248 amino acid substitution
in L that specified a 38°C shut-off temperature, were not
additive with those of the 404-M2 mutation. Rather, the
temperature sensitivity and attenuation specified by the
248 mutation was masked by that specified by the
404-M2 mutation. These findings in the context of other
observations indicate that a combination of two or more
ts mutations into one virus can have one of four effects:
(1) they can be additive (Subbarao et al., 1995); (2) they
can be nonadditive, as in the present study, with the
temperature sensitivity of the double mutant reflecting
that of the more ts member; (3) the combination of two ts
mutations can result in a virus that is less ts than either
parent (Ramig and Fields, 1979; Skiadopolous et al.,
1998); and (4) the combination of ts mutations derived
from different viruses can be lethal (Whitehead et al.,
unpublished observation). Given these observations, it
will be difficult to predict the effect of combining two ts
mutations into a single virus.
Because the GS signal appears 10 times in the RSV
genome, namely at the beginning of each gene, the
finding that a single nucleotide change within the signal
confers profound ts and att phenotypes offers interesting
possibilities. It may be that the introduction of this mu-
tation into one or more other genes will confer desirable
att phenotypes. For example, introduction of the mutation
into a gene that is more proximal to the 39 end might
confer a more profound biological effect, both because
such products are presumably required in greater
amounts and because the mutation might disrupt se-
quential transcription and thereby affect multiple genes.
It also may be possible to place this mutation into mul-
tiple GS signals and thereby augment attenuation and
increase phenotypic stability. We are presently testing
whether the mutant phenotype is transportable with this
single substitution, as would be expected, or whether a
larger sequence context is required.
The findings from the present study have specific
implications for the further development and clinical
evaluation of the cpts248/404 vaccine candidate. The
identification of the mutations in cpts248/404 that confer
the ts and att phenotypes permits us to monitor the
presence of the relevant attenuating mutations through
all phases of manufacture and clinical evaluation. In
addition, the finding that the major determinant of the
attenuation of cpts248/404 results from a single nucleo-
tide substitution (404-M2 mutation) raises concerns
about the phenotypic stability of this vaccine candidate.
The evaluation of cpts248/404 in seronegative chimpan-
zees and of its immediate precursor, cpts248, in immu-
nosuppressed mice has not revealed a tendency for
cpts248/404 to lose temperature sensitivity following
replication in vivo (Crowe et al., 1994a,b). This relatively
high level of genetic stability likely reflects the contribu-
tions of separate mutations to the ts and att phenotypes,
namely the set of non-ts cp mutations (Friedewald et al.,
1968; Connors et al., 1995; Whitehead et al., 1998) and
the 248 and 404-M2 mutations. It is reasonable to sug-
gest that the combination of ts and non-ts attenuating
mutations in rA2cp248/404 act together to augment the
stability of the ts and att phenotypes of the virus because
other phenotypically stable, live-attenuated vaccines and
vaccine candidates, including para- and orthomyxovi-
ruses and polioviruses, have both ts and non-ts muta-
tions contributing to attenuation (Snyder et al., 1988;
Westrop et al., 1989Hall et al., 1992; Tatem et al., 1992;
Crowe et al., 1994b; Bouchard et al., 1995). In contrast,
several candidate vaccines that contained only ts muta-
tions contributing to their att phenotype have proven to
be unstable and have readily lost their temperature sen-
sitivity in animals or humans (Tolpin et al., 1981; Snyder
et al., 1988; Crowe et al., 1994a; Murphy et al., 1997).
However, reversion at the 404-M2 locus is possible and
would yield a virus still containing the 248 and the cp
attenuating mutations. Such a revertant virus should ex-
hibit an intermediate level of attenuation and tempera-
ture sensitivity, and in fact, this possibility was recently
observed during clinical trials with cpts248/404 in young
infants (P. Wright et al., unpublished observations). A
cpts248/404 isolate that was obtained from a vaccinee
who shed virus very late in the course of infection was
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less temperature sensitive than the input virus. Se-
quence analysis of this isolate revealed a nucleotide
substitution at the position of the 404-M2 mutation. In-
terestingly, however, this position had not reverted to the
wt assignment (T), but rather was changed to a third
assignment (A), which matches that found in the unique
L gene start signal (unpublished observations).
If mutant virus cpts248/404 is found to be insufficiently
attenuated in humans, we are in a position to introduce
additional ts and non-ts mutations into the rA2cp248/404
genetic background. We are in the process of identifying
the genetic basis of temperature sensitivity and attenuation
of a panel of ts viruses, such as cpts530/1009 and cpts530/
1030, which were also derived from cpRSV. Addition of one
or more of these mutations, as well as the recently de-
scribed deletion of the SH gene of RSV (Bukreyev et al.,
1997), which is a non-ts attenuating mutation, should in-
crease the level of attenuation of the virus and should also
increase its phenotypic stability. In this systematic way, we
believe it will be possible to create a satisfactorily attenu-
ated RSV vaccine in the near future.
MATERIALS AND METHODS
Cells and viruses
The subgroup A wild-type RSV A2 strain (wtRSV
HEK-7) and its biologically derived RSV mutants cpRSV,
cpts248 and cpts248/404 were grown in HEp-2 or Vero
cells as previously described (Crowe et al., 1994a,b;
Connors et al., 1995). Cell monolayer cultures were main-
tained in Opti-MEM I (Life Technologies, Inc., Grand
Island, NY) supplemented with 4% fetal bovine serum
(Summit Biotechnology, Ft. Collins, CO) and 0.05 mg/ml
gentamicin (Quality Biological, Inc., Gaithersburg, MD).
The modified vaccinia virus Ankara recombinant ex-
pressing the bacteriophage T7 RNA polymerase (MVA/T7
pol) was provided by L. Wyatt and B. Moss and grown in
primary chick embryo cells (Wyatt et al., 1995).
Site-directed mutagenesis and assembly
of cDNA clones
The three nucleotide substitutions found in cpts248
and cpts248/404 were introduced singly or together into
a modified cDNA representing the parental cpRSV ge-
nome as previously described (Juhasz et al., 1997; White-
head et al., 1998). To introduce the 248 and 404-L muta-
tions into the L gene, a cassette spanning the first half of
the L gene, nucleotides 8501–12255, was subcloned into
modified pUC119. To introduce the 404-M2 mutation into
the M2 gene start signal, a cassette spanning the F and
M2 genes, nucleotides 5613–8501, was subcloned into
pUC118. The sequence changes shown in Table 1 were
made in these clones by site-directed mutagenesis
(Kunkel et al., 1987) and then were introduced in various
combinations into the full-length cpRSV cDNA (D53cp) to
create six novel constructs suitable for generating re-
combinant RSV. Each mutation was tagged by an accom-
panying restriction enzyme cleavage site, which was
designed to be translationally silent. All sequence
changes were confirmed by nucleotide sequencing. In
the final D53cp-based cDNA constructs, the presence of
the 248, 404-M2 and 404-L mutations, as well as the 13
other mutations found in D53cp (Whitehead et al., 1998),
was confirmed by restriction enzyme analysis.
Production of recombinant RSV
Transfection and recovery of recombinant RSV was
performed as previously described (Collins et al., 1995).
Briefly, HEp-2 cell monolayers infected at a multiplicity of
infection of 3 with MVA/T7 pol were transfected with a
full-length D53 cDNA along with the pTM1-based N, P, L,
and M2–1 expression plasmids using LipofectACE re-
agent (Life Technologies, Inc.). After 3 days incubation at
32°C, clarified cell culture supernatants were passaged
onto fresh HEp-2 cell monolayers that were incubated for
5 days at 32°C for the purpose of virus amplification.
Virus was quantified by direct plaque titration using
monoclonal antibody horseradish peroxidase staining as
described (Murphy et al., 1990). To ensure a homoge-
neous virus population, recombinant viruses were bio-
logically cloned by three successive plaque purifications
and then amplified two to three times on HEp-2 cell
monolayers to produce virus suspensions suitable for
characterization.
Virus characterization
The presence of the introduced mutations in the ge-
nome of recombinant viruses was confirmed by RT-PCR
and restriction enzyme analysis. Briefly, virus particles
were concentrated from clarified virus suspension by
adding PEG-8000 to a final concentration of 7.5% (w/v).
After incubation on ice for 2 h, virus was recovered by
centrifugation at 12,000 g for 1 h. Genomic RNA was
purified from the viral pellet by extraction with TRIzol
reagent (Life Technologies, Inc.), and RT was performed
using the SuperScript preamplification system (Life Tech-
nologies, Inc.) and random hexamer primers. Four re-
gions of the genome were amplified using the Advantage
cDNA PCR kit (Clontech Laboratories, Inc., Palo Alto,
CA). The PCR fragments, corresponding to nucleotides
1128–2451 (N gene region), 5347–8463 (F–M2 gene re-
gion), 8611–12608 (upstream L region), and 12568–14985
(downstream L region) of the recombinant RSV genome,
were digested with the appropriate restriction enzyme
and analyzed on 1% agarose gels to confirm the pres-
ence of the restriction enzyme sites accompanying the
introduced mutations.
The ts phenotype of the recombinant viruses was
evaluated by determining the efficiency of plaque forma-
tion at various temperatures as previously described
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(Crowe et al., 1993). Plaque titration was performed at 32,
36, 37, 38, 39, and 40°C on HEp-2 cell monolayers incu-
bated 5 days in temperature-controlled water baths.
Plaques were enumerated by antibody staining as indi-
cated above.
The replication of recombinant viruses was evaluated
in the upper and lower respiratory tracts of mice as
described (Crowe et al., 1994b). Briefly, respiratory-
pathogen-free 10-week–old BALB/c mice in groups of
five were inoculated intranasally under methoxyflurane
anesthesia on day 0 with 106 pfu of RSV per animal in a
0.1 ml inoculum. On day 4, mice were sacrificed by
carbon dioxide inhalation, and nasal turbinates and lung
tissue were harvested and homogenized separately in
phosphate-buffered Hanks’ balanced salt solution (pH
6.9) containing 7.5% sucrose, 5 mM sodium glutamate,
0.05 mg/ml ciprofloxacin, 0.05 mg/ml clindamycin phos-
phate, and 0.0025 mg/ml amphotericin B. Virus titers are
expressed as mean log10pfu/g tissue 6 standard error.
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